Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events

Archives of Internal Medicine

Volumn 161, Issue 7, 2001, Pages 957-964

  Cohen, J S ^a  

^a Box 120 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE BESYLATE; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; CELECOXIB; CONJUGATED ESTROGEN; DICLOFENAC; FLUOXETINE; HYDROCHLOROTHIAZIDE; IBUPROFEN; LISINOPRIL; OMEPRAZOLE; RAMIPRIL;

ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG INFORMATION; HUMAN; INCIDENCE; MEDICAL LITERATURE; PATIENT COMPLIANCE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0035832016     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.7.957     Document Type: Article

References (124)

1. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies
2. Drugs and adverse drug reactions: How worried should we be?
3. Pharmacogenetics: The individual response to drugs
4. Adverse-drug-reaction reporting
5. Physicians' Desk Reference. 53rd ed.
6. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development
7. Evaluating drugs after their approval for clinical use
8. The Physicians' Desk Reference: Problems and possible improvements
9. Knowledge resource preferences of family physicians
10. The information needs of family physicians: Case-specific clinical questions
11. "Not just a statistic": The history of USA and UK policy over thrombotic disease and the oral contraceptive pill, 1960s-1970s
12. JNC guidelines: Is the message getting through?
13. Trends in antihypertensive drug use in the United States: Do the JNC V recommendations affect prescribing?
14. 34th annual top 200 drug issue
15. Estrogen-progestin combinations for postmenopausal use
16. Symptom relief and side effects of postmenopausal hormones: Results from the Postmenopausal Estrogen/Progestin Interventions trial
17. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women
18. A practical guide to prescribing estrogen replacement therapy
19. Personal perspective on low-dosage estrogen therapy for postmenopausal women
20. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: A randomized, controlled trial
21. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: A 2-year prospective study
22. Adherence to pharmacologic management of hypertension
23. Compliance in the treatment of hypertension: A need for action
24. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
25. Adverse drug effects, compliance, and initial doses of antihypertensire drugs recommended by the Joint National Committee vs the Physicians' Desk Reference
26. Dose-response for analgesic effect of amitriptyline in chronic pain
27. Application of an individually predicted dosage of amitriptyline to the treatment of depression
28. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor
29. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects
30. Using newer antidepressants in the medically ill: An update
31. Private practice evaluation of the safety and efficacy of bupropion in depressed outpatients
32. Efficacy of bupropion in tricyclic-resistant or intolerant patients
33. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
34. Clinical efficacy and safety of cerivastatin: Summary of pivotal phase IIb/III studies
35. International multicentre comparison of cerivastatin with placebo and simvastatin for the treatment of patients with primary hypercholesterolaemia
36. Determining the optimal dosage regimen for H2-receptor antagonist therapy: A dose validation approach
37. Diclofenac in the treatment of primary dysmenorrhoea
38. Diclofenac sodium (Voltaren): Results of a multi-centre comparative trial in adult-onset rheumatoid arthritis
39. Use of diclofenac in analgesia
40. Reduced diclofenac administration by B vitamins: Results of a randomized double-blind study with reduced daily doses of diclofenac (75 mg diclofenac versus 75 mg diclofenac plus B vitamins) in acute lumbar vertebrel syndromes
41. Diclofenac in the treatment of painful joints and traumatic tendinitis (including strains and sprains): A brief review
42. Diclofenac sodium (Voltaren) and indomethacin in the ambulatory treatment of rheumatoid arthritis: A double-blind multicentre study
43. Long-term comparative study: Diclofenac (Voltaren) and naproxen (Proxen) in arthritis
44. Report on a long-term tolerability study of up to two years with diclofenac sodium (Voltaren)
45. The value and results of long-term studies with diclofenac sodium (Voltarol)
46. Using tricyclic antidepressants in the elderly
47. Medications and the older driver
48. Low bedtime doses of H2-receptor antagonists for acute treatment of duodenal ulcers
49. Effects of low and high doses of famotidine and ranitidine on nocturnal gastric pH
50. Efficacy and safety of fexofenadine in fall seasonal allergic rhinitis
51. Low-dose fluoxetine therapy for depression
52. Use of low-dose fluoxetine in major depression and panic disorder
53. Practical considerations in the pharmacologic treatment of depression and anxiety in the elderly
54. Dosing strategies for antidepressant agents
55. The role of SSRIs in panic disorder
56. The pharmacotherapy of minor depression
57. Poor response to fluoxetine: Underlying depression, serotonergic over-stimulation, or a "therapeutic window"?
58. Evaluation of drug efficacy by a preference technic
59. Comparative studies with a hypnotic (RO 5-6901) under current investigation
60. Sleep laboratory studies of flurazepam: A model for evaluating hypnotic drugs
61. Further experience with ibuprofen in the treatment of arthritis
62. Low dose ibuprofen and aspirin analgesia for postpartum uterine cramps
63. An evaluation of ibuprofen 200mg, ibuprofen 400mg and naproxen 200mg and 400mg in postoperative oral surgery pain
64. The relative efficacy of ibuprofen in dental pain
65. Five studies on ibuprofen for postsurgical dental pain
66. The effects of ibuprofen in the treatment of dysmenorrhea
67. Clinical experience with ibuprofen in the treatment of rheumatoid arthritis
68. Ibuprofen and aspirin in the treatment of rheumatoid arthritis: A cooperative double-blind trial
69. The pharmacological profile of non-opioid (OTC) analgesics: Aspirin, parecetamol (acetaminophen), ibuprofen, and phenazones
70. Nonlinear kinetics of imipramine in low and medium plasma level ranges
71. Successful treatment of severe anxiety attacks with tricyclic antidepressants: A potential mechanism of action
72. Antidepressants in panic disorder and agoraphobia
73. Behavior therapy, supportive psychotherapy, imipramine, and phobias
74. Pharmacokinetics of antidepressants: Why and how they are relevant to treatment
75. Cholesterol-lowering effects of a 10 mg daily dose of lovastatin in patients with initial cholesterol levels 200 to 240 mg/dL (5.18 to 6.21 mmol/liter)
76. Hypercholesterolemia in postmenopausal women: Metabolic defects and response to low-dose lovastatin
77. Reduction of aspirin-induced fecal blood loss with low-dose misoprostol tablets in man
78. Gastrointestinal cytoprotective effects of misoprostol: Clinical efficacy overview
79. A double-blind placebo-controlled comparison of the efficacy and safety of 50, 100, and 200 micrograms of misoprostol QID in the prevention of ibuprofen-induced gastric and duodenal mucosal lesions and symptoms
80. Misoprostol reduces gastroduodenal injury from one week of aspirin: An endoscopic study
81. A double-blind comparison of nefazodone, imipremine, and placebo in major depression
82. Nefazodone in the treatment of premenstrual syndrome: A preliminary study
83. Nefazodone and imipramine in major depression: A placebo-controlled trial
84. New dosing strategies for psychotropic drugs
85. Healing and subsequent recurrence of duodenal ulcer in a clinical trial comparing nizatidine 300-mg and 100-mg evening doses and placebo in the treatment of active duodenal ulcer
86. Treatment of duodenal ulcers in the United States
87. Efficacy of nizatidine: A new H2 receptor antagonist in the treatment of duodenal ulcer: A dose response study
88. Clinical pharmacology of antidepressant drugs: Pharmacogenetics
89. A multinational study of the effects of low-dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia
90. Once-daily pravastatin in patients with primary hypercholesterolemia: A dose-response study
91. Effect of 10 mg and 20 mg omeprazole daily on duodenal ulcer: Double-blind comparative trial
92. Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse: Double-blind comparative trial
93. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy
94. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: Review of clinical trials
95. Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies
96. Treatment of duodenal ulcer with ranitidine, a new histamine H2-receptor antagonist
97. Placebo controlled studies with ranitidine in duodenal ulcer
98. Endoscopic double-blind controlled trial of ranitidine vs placebo in the short-term treatment of duodenal ulcer
99. Ranitidine and cimetidine for duodenal ulcer
100. Panic attacks precipitated by sertraline
101. Low-dose effect of simvastatin on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia
102. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia
103. Dose-response of simvastatin in primary hypercholesterolemia
104. The clinical efficacy of lovastatin and MK-733 (simvastatin): An overview
105. Effect of low-dose simvastatin on cholesterol levels, oxidative susceptibility, and antioxidant levels of low-density lipoproteins in patients with hypercholesterolemia: A pilot study
106. Comparison of the effects of pravastatin and simvastatin in hypercholesterolemic subjects
107. A drug utilization review of prescribing patterns for trazodone vs. amitriptyline
108. Guidelines for prescribing psychoactive drugs in the elderly: Part 1
109. Recent studies on selective serotonergic antidepressants: Trazodone, fluoxetine, and fluvoxamine
110. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study
111. Venlafaxine treatment of panic disorder: A case series
112. Testing the effects of the imidazopyridine zolpidem on memory: An ecologically valid approach
113. The dose effects of zolpidem on the sleep of healthy normals
114. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs
115. Persistence of use of lipid-lowering medications: A cross-national study
116. The underused miracle drugs: The statin drugs are to atherosclerosis what penicillin was to infectious disease
117. Prevalence and determinants of estrogen replacement therapy in elderly women
118. Mechanism of the cardiotoxic actions of terfenadine
119. Clinical investigation of terfenadine, a non-sedating antihistamine
120. Clinical studies of terfenadine in seasonal allergic rhinitis